The successful introduction of the MOPP combination chemotherapy regimen in 1964 at the National Cancer Institute (US) has proved to be a huge step forward in the treatment of Hodgkin's disease (De Vita et al., 1980; Longo et al., 1986) . The complete remission rate of 84% with overall survival of 48% for a group of patients, most of whom had advanced disease, remains the standard by which alternative treatments for Hodgkin's disease must be measured. Nevertheless, there are substantial residual problems with the chemotherapy of Hodgkin's disease. Its efficacy is still limited and 40-50% of patients either fail to enter complete remission or relapse after chemotherapy with MOPP. The toxicity of MOPP and related combinations is substantial with acute haematological, gastroenterological and neurological toxicity followed by long term gonadal toxicity and the development of second malignancies, particularly acute myeloid leukaemia . For the past 20 years, research on the chemotherapy of Hodgkin's disease has sought to reduce the toxicity and increase the efficacy of chemotherapy regimens.
In 1975 we introduced the ChlVPP (chlorambucil, vinblastine, procarbazine and prednisolone) regimen at the Royal Marsden Hospital. In our practice this superseded a MOPPbased regimen known as MVPP in which vincristine was replaced with vinblastine. Analyses in 1977 and 1982 suggested that the ChlVPP regimen was an effective low-toxicity combination chemotherapy for Hodgkin's disease (McElwain et al., 1977; Dady et al., 1982) . Moreover, a randomised prospective trial compared chlorambucil-based combination chemotherapy with mustine-based combination chemotherapy and concluded that the regimens were of comparable efficacy (British National Lymphoma Investigation, 1986) . In this report, we describe the long term efficacy and toxicity of the ChlVPP regimen in 284 adults who had received no previous chemotherapy for their Hodgkin's disease.
Patients and methods
Between January 1975 and March 1986, 284 (Robinson et al., 1984) .
All records were reviewed retrospectively and for each reviewer at least 10% of the findings were independently checked by one other reviewer. If more than 5% of the findings of a single contributor were in disagreement with the second reviewer, a complete reanalysis of those patients was performed. Bulk of disease at peripheral sites was defined as masses greater than 5 cm and bulk in the mediastinum was defined as a ratio of the maximum diameter of the mass to the maximum diameter of the thorax of greater than 33%. Haematological and biochemical tests were recorded and the records of all imaging tests were reviewed. Histology was reviewed for all patients at RMH. Histological classification was by the criteria of Lukes and Butler (1966) , and staging was according to the Ann Arbor System (Carbone et al., 1971) . Toxicity according to WHO scales (World Health Organization, 1979) was retrospectively analysed by review of the hospital records.
Patients were assessed by a full clinical history and physical examination, full blood count, erythrocyte sedimentation rate, serum biochemistry and liver function tests, chest X-ray, lymphogram and bone marrow aspirates with trephine. CT scan of the mediastinum and abdomen, hepatic ultrasound and isotope liver scan, gallium scan and staging laparotomy were performed only when clinically indicated. A staging laparotomy was performed in 104 of 229 previously untreated patients and 6 of 55 who had had previous radiotherapy. During treatment, patients were reassessed prior to each course of ChIVPP by physical examination, chest X-ray, abdominal X-ray, and full blood count. At the end of chemotherapy patients were restaged by repeating all investigations which had been found to be abnormal before chemotherapy was given. The timing of complete remission is therefore defined by physical examination and the interim investigations but the proportion of patients entering complete remission is defined by full restaging investigations. A complete remission is defined as a return to normal for all findings on examination and on repeat of all previously abnormal investigations. The significance of an abnormal mediastinal contour on chest X-ray may present great difficulty in interpretation and is discussed below.
For patients who have relapsed from previous radiotherapy, the Ann Arbor Staging System should not be applied directly and it was not designed for this purpose (Carbone et al., 1971) . In attributing stages to such patients, we have used the Ann Arbor recommendations but included all known sites of disease (before and after radiotherapy) in the estimation of stage. These allocations of 'cumulative stage' at relapse must be distinguished from stage at presentation. Survival duration and relapse-free interval for patients who achieved complete remission were both measured from the date of first chemotherapy. The curves presented were calculated using the method of Kaplan and Meier (1978) and the log rank test (Peto et al., 1977) was used to compare the curves. The percentages of patients remaining in remission and surviving at 5 and 10 years given in Tables I and II are obtained from such curves. For continuous variables, different groupings were examined to determine those which most influenced survival and remission durations. A stepwise linear regression analysis based on Cox's proportional hazards model (Cox, 1972) was performed to assess the relative importance of the various factors in determining the survival duration and relapse-free interval for this group of patients. Table I includes the basic demographic and clinical features of the 229 patients who had had no previous treatment. In Table II abbreviated data are given for 55 patients who had relapsed from previous radiotherapy. The median follow-up for surviving patients is 92 months.
Results

Patient characteristics
Treatment
The median number of courses for all patients was 6 (range 1-16) and 174 of 284 patients received 6 courses. Seven patients received 7 courses; 14 received 8 courses; 4 received 9 courses; 12 received 10 courses and 1 received 16 courses. One hundred and twenty-eight previously untreated patients received elective radiotherapy following their chemotherapy. Tables I and II give complete remission rates together with the observed probability of continuing remission and survival at 5 and 10 years after treatment. The overall CR rate was 85% (no previous treatment) and 91% (previous radiotherapy). The 10 years probability of survival was 65% and 67% for these two groups respectively and 20-25% of CR patients relapsed. Duration of remission and survival curves are shown in Figures 1 and 2 . The overall survival and relapse curves for patients who had no previous treatment and those who had previous radiotherapy are similar (Figure la and b) .
Efficacy
Among 128 patients who received radiotherapy after chemotherapy the CR rate was 95% while among 101 patients who received chemotherapy alone the CR rate was 71%. However, the policy in patients who failed to remit on ChlVPP chemotherapy was to switch to alternative chemotherapy regimens, which means that the selection of cases for the no-radiotherapy group was influenced by their response and the difference between the two groups is inevitably biased. There were 21 patients within the group who received elective radiotherapy after chemotherapy who entered CR after receiving combined modality treatment but were not felt to be in CR after the chemotherapy. Fourteen of these had residual abnormalities of the mediastinal contour after shrinkage of bulky mediastinal disease and the true significance of this remains uncertain. The remaining 7 had residual disease at other sites after chemotherapy.
For previously untreated patients Table III summarises the results of a univariate analysis to examine the influence of all of the factors listed in Table I as well as ESR, haemoglobin, alkaline phosphatase, hepatic transaminase, gamma glutamyl transpeptidase on CR, relapse and survival. The important prognostic factors which emerged from this analysis for the previously untreated group of patients are given below.
Age (Figure 2a and b) . The age distribution is unremarkable for HD with median 30, range 16-81. The main prog- (Figure 2c-f) .
Sites Figure 3 is a partial cumulative probability plot relating survival to cause of death. The majority of patients died of or with active Hodgkin's disease and among those who died in remission, immunosuppression was the most important factor. Second malignancies -only some of which may be linked to treatment -were only a minor cause of death in this series (Figure 3 ).
Discussion
The results described for the efficacy of the ChlVPP regimen in this single institution series compare favourably with any previous results described for the combination chemotherapy of advanced Hodgkin's disease with MOPP or regimens (Longo et al., 1986 (Tucker et al., 1988; Colman & Selby, 1987) .
The use of mustine based combination chemotherapy is now inappropriate in the management of Hodgkin's disease and owes more to tradition than to clinical science. There are equally effective alternative alkylating agents and among these, chlorambucil is one less toxic choice.
The ChlVPP regimen can be given in full doses and without delay to the majority of patients which may be in part responsible for the observed efficacy. The small number of patients for whom dose reductions or delays are necessary precludes a formal analysis of the intensity of treatment as a determinant of outcome in this study. The rather lower complete remission and survival rates observed with other chlorambucil based regimens which have lower doses of chlorambucil and procarbazine (British National Lymphoma Investigation, 1986 ) suggest that the treatment should be used in the doses described in this paper without dose reduction or modification if this can be avoided.
The factors which we have observed to influence the outcome of treatment with the ChlVPP regimen are broadly in keeping with those seen in other series with other regimens (see Selby et al., 1987) . Age and disease affecting liver, lung and bone marrow are powerful predictors of outcome and achieving CR is the most important determinant of survival. Some differences exist between the importance of the factors described here and important prognostic factors found elsewhere in the literature (Wagstaff et al., 1988 ; reviewed by Selby et al., 1987) . These differences are more likely to be due to differing patient populations and selection together with differing institutional practice for investigation and data collection than to be due to any real biological differences. For instance, Wagstaff et al. (1988) found age, sex, lymphocyte count and stage to be independent indicators of survival in the Barts/Christie series. We were unable to include lymphocyte count in our multivariate analysis because our data were incomplete. We found no difference in survival according to sex on univariate or multivariate analysis. We cannot fully explain the discrepancy but the patient populations differ in stage and treatment so that all comparisons are tentative. For these reasons we do not propose to develop any prognostic models or indices based upon the observations in the present series.
The development of ChlVPP combination chemotherapy has reduced the toxicity and need for hospitalisation of patients undergoing chemotherapy for Hodgkin's disease. It can be given easily, routinely and safely in outpatients and many patients continue to work normally. This regimen is, however, associated with secondary acute leukaemia in a small number of cases in this series and is associated with infertility in the majority of men and a minority of younger women (Sutcliffe, 1987) .
The principal problem in the future development of chemotherapy for Hodgkin's disease remains the need for more effective treatment which will reduce the 30-50% of patients whose disease is not cured by existing regimens.
Failure to remit and early relapse are the major risks to our patients. The advantages of adriamycin based regimens or of alternation of alkylating agent based regimens with adriamycin based regimens remain uncertain but recent clinical trials are suggesting an advantage for the use of an adriamycin based regimen such as ABVD either alone or in alternation with MOPP or its variants (Bonnadonna et al., 1985 ; review by Selby et al., 1987) . In addition the use of high dose treatment with autologous bone marrow grafting is allowing salvage of a proportion of patients who relapse from conventional dosage chemotherapy (Russell et al., 1989; Zulian et al., 1989) . Chlorambucil based combination chemotherapy represents a substantial step towards reducing the burden of combination chemotherapy upon the patient with advanced Hodgkin's disease but there remain many problems to be solved.
